IRONWOOD PHARMACEUTICALS, INC. Fair Value, Assets, Level 1 to Level 2 Transfers, Amount
IRONWOOD PHARMACEUTICALS, INC. (IRWD) had Fair Value, Assets, Level 1 to Level 2 Transfers, Amount of $0 as of 2015-06-30, per its 10-Q filed 2015-08-07.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount · last filed 2015-08-07
- 2015-06-30: Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $0.00.
- 2015-03-31: Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $0.00.
- 2014-12-31: Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $0.00.
- 2014-09-30: Fair Value, Assets, Level 1 to Level 2 Transfers, Amount $0.00.
| Period end | Fair Value, Assets, Level 1 to Level 2 Transfers, Amount |
|---|---|
| 2015-06-30 | $0.00 10-Q · filed 2015-08-07 |
| 2015-03-31 | $0.00 10-Q · filed 2015-05-06 |
| 2014-12-31 | $0.00 10-K · filed 2015-02-18 |
| 2014-09-30 | $0.00 10-Q · filed 2014-11-05 |
| 2014-06-30 | $0.00 10-Q · filed 2015-08-07 |
| 2014-03-31 | $0.00 10-Q · filed 2015-05-06 |
| 2013-12-31 | $0.00 10-K · filed 2015-02-18 |
| 2013-09-30 | $0.00 10-Q · filed 2014-11-05 |
| 2013-06-30 | $0.00 10-Q · filed 2014-08-05 |
| 2013-03-31 | $0.00 10-Q · filed 2014-04-29 |
| 2012-12-31 | $0.00 10-K · filed 2014-02-07 |
| 2012-09-30 | $0.00 10-Q · filed 2013-10-28 |
| 2012-06-30 | $0.00 10-Q · filed 2013-08-08 |
| 2012-03-31 | $0.00 10-Q · filed 2013-04-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |